我们进行了一项多中心的回顾性观察研究，旨在探讨免疫检查点抑制剂（ICI）对肾细胞癌（RCC）骨转移（BM）患者生存率的影响。我们回顾性地纳入了98例接受ICI治疗的转移性RCC（mRCC）患者。所有患者在2015年12月至2022年3月期间接受了尼伐单抗单独或与伊匹单抗联合的标准治疗。主要终点为中位总生存期（OS）。43例患者（44%）有BM的影像证据。BM患者与整个人群的OS之间没有统计学上显著的差异（p = 0.254）。我们的研究表明ICI在治疗来自RCC的BM患者中具有一定的活性，而此类患者在历史上与较差的预后相关。版权所有 2023, 国际抗癌研究所。

We performed a multicenter retrospective observational study to investigate the impact of immune checkpoint inhibitors (ICIs) on the survival of patients with bone metastases (BMs) from renal cell cancer (RCC).A total of 98 patients with metastatic RCC (mRCC) treated with ICIs were retrospectively enrolled. All patients received standard treatments with nivolumab alone or in combination with ipilimumab from December 2015 to March 2022. The primary endpoint was median overall survival (OS).Forty-three patients (44%) had radiological evidence of BMs. No statistically significant difference in OS was reported between the BM population and the entire population (p=0.254).Our study suggests some degree of ICI activity to treat patients with BMs from RCC, historically associated with a poorer prognosis.Copyright 2023, International Institute of Anticancer Research.